Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Fertility and sterility. 2017 Feb 8. pii: S0015-0282(16)63071-6. doi: 10.1016/j.fertnstert.2016.12.003
    Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study.
    Muin DA1,  Sheikh Rezaei S2,  Tremmel-Scheinost M3,  Salama M4,  Luger A5,  Wolzt M6,  Husslein PW7,  Bayerle-Eder M8
    Author information
    1Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
    2Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
    3Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
    4Department of Thoracic Surgery, Otto-Wagner-Spital, Vienna, Austria.
    5University Clinic of Internal Medicine III, Department of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria.
    6Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
    7Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria.
    8University Clinic of Internal Medicine III, Department of Endocrinology and Metabolism, Medical University of Vienna, Vienna, Austria. Electronic address: Michaela.Bayerle-Eder@meduniwien.ac.at.
    Abstract

    OBJECTIVE: To study sexual function, quality of life, and depression in men, whose female partners are undergoing double-blind placebo-controlled randomized treatment for hypoactive sexual desire disorder (HSDD).

    DESIGN: Open prospective cohort study of 22 weeks.

    SETTING: Academic medical center.

    PATIENT(S): Male partners of 30 premenopausal and postmenopausal women with HSDD.

    INTERVENTION(S): Baseline, 3-month, and 5-month assessment (for 8 weeks each) of male response to female partner's use of oxytocin nasal spray (32 IE) and placebo within 50 minutes before sexual intercourse.

    MAIN OUTCOME MEASURE(S): Primary outcome parameters were Sexual Life Quality Questionnaire-Male, Sexual Activity Record, Partner Performance Questionnaire, and Hamilton Depression Scale.

    RESULT(S): Male Sexual Life Quality questionnaire improved significantly from -7.4 ± 9.9 at baseline to 8.2 ± 12 with female partners' treatment with oxytocin nasal spray and to 10.8 ± 13.8 with placebo. Frequency of intercourse improved slightly but not significantly from 6.3 ± 3.9 at baseline to 7.3 ± 4 with female oxytocin therapy, but not with placebo. Male desire and arousal remained stable throughout the study period. Evaluation of female partners' performance by men improved significantly from 8.9 ± 2.8 at baseline to 10.6 ± 2.2 with oxytocin and to 11.2 ± 2.6 with placebo.

    CONCLUSION(S): Female treatment with either oxytocin or placebo for HSDD significantly improves male sexual quality of life and evaluation of female partner's sexual performance with no difference between oxytocin and placebo on any outcome parameters. A nonsignificant improvement was seen in the frequency of intercourse, male arousal, desire, satisfaction, and Hamilton depression scale.

    CLINICAL TRIAL REGISTRATION NUMBER: NCT02229721.


    Copyright © 2016 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

    KEYWORDS: Male sexual function, hypoactive sexual desire disorder, oxytocin, quality of life

    Publikations ID: 28189292
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt